Imagine a world where HIV treatment is not only effective but also resistant to the very challenges that threaten its success. That’s exactly what researchers at Queen Mary University of London are working toward, and their latest breakthrough could change the game for millions living with HIV. But here’s where it gets even more groundbreaking: they’ve developed the first non-integrase strand-transfer inhibitor (non-INSTI) single-tablet treatment, a move that comes at a critical time as concerns grow over widespread INSTI resistance in resource-limited regions.
Published in The Lancet (https://www.sciencedirect.com/science/article/pii/S0140673625019452), the phase 3 trial results reveal that the once-daily combination of doravirine and islatravir is both safe and effective. This is huge because, while current HIV treatments rely heavily on INSTIs to block the virus from integrating into the genome, emerging data from WHO regions show troubling signs of resistance. And this is the part most people miss: if INSTI resistance becomes widespread, it could jeopardize the long, healthy lives that people with HIV now expect.
Here’s why this matters: INSTIs are the gold standard in HIV treatment due to their high efficacy, low risk of resistance, and minimal side effects. They’re being rolled out globally, especially in low-income areas. But the rise of resistance underscores the urgent need for alternatives—like this new non-INSTI option.
Led by Professor Chloe Orkin, Director of the SHARE Collaborative at Queen Mary University of London, the study stands out for another reason. It included far more women, older adults, and racially minoritized individuals than typical HIV trials, addressing a chronic gap in representation. Professor Orkin is no stranger to innovation—she also spearheaded the development of the first long-acting injectable HIV treatment, Cabotegravir and Rilipivirine.
“This is an important moment in the development of HIV treatments,” Professor Orkin emphasized. “INSTI resistance could have huge consequences, so novel treatments like doravirine/islatravir are critical. Plus, islatravir’s long-acting potential—currently being tested as a weekly tablet—makes its success as a daily pill a significant milestone toward more convenient, long-acting options.”
But here’s the controversial question: As we celebrate this breakthrough, should we also be reevaluating our reliance on INSTIs in regions where resistance is already emerging? And what does this mean for the future of HIV treatment in low-resource settings?
This isn’t just a scientific achievement—it’s a beacon of hope for a future where HIV treatment is not only effective but adaptable. What’s your take? Do you think this new treatment could be the key to staying ahead of resistance, or are there other factors we need to consider? Let’s discuss in the comments!
